Circulating tumor DNA validity and potential uses in metastatic breast cancer.
Ottavia AmatoNefeli GiannopoulouMichail IgnatiadisPublished in: NPJ breast cancer (2024)
Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s, recent advances led to its introduction in the clinics. At present, the European Society Of Medical Oncology (ESMO) recommendations endorse ctDNA testing in routine clinical practice for tumor genotyping to direct molecularly targeted therapies in patients with metastatic cancer. In studies on metastatic breast cancer, ctDNA has been utilized for treatment tailoring, tracking mechanisms of drug resistance, and for predicting disease response before imaging. We review the available evidence regarding ctDNA applications in metastatic breast cancer.
Keyphrases
- circulating tumor
- metastatic breast cancer
- clinical practice
- cell free
- circulating tumor cells
- primary care
- healthcare
- papillary thyroid
- high resolution
- palliative care
- genome wide
- squamous cell carcinoma
- dna methylation
- photodynamic therapy
- combination therapy
- human health
- replacement therapy
- mass spectrometry
- nucleic acid